Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
Meng Li, Xueyu Zhao, Chuanfei Yu, et al.
Pharmaceutical Research (2024) Vol. 41, Iss. 3, pp. 419-440
Closed Access | Times Cited: 9
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Herui Yao, Min Yan, Zhongsheng Tong, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 29, pp. 3453-3465
Closed Access | Times Cited: 9
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 8
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
Hongyan Zhang, Longlong Zhang, Yuna He, et al.
Cancer Letters (2024) Vol. 598, pp. 217112-217112
Closed Access | Times Cited: 6
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Khalil Saleh, Rita Khoury, Nadine Khalife, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 5
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer
Sabrina Nucera, Chiara Conti, Federica Martorana, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1491-1491
Open Access | Times Cited: 5
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Antibody–Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
Prathana Nathan, Adnan Rajeh, Meh Noor, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2316-2327
Open Access | Times Cited: 4
Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies
Seiichiro Takao, Hiroshi Fukushima, Aki Furusawa, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
Yue Qiu, Y. Eric Shi, Zhujun Chao, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access
Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
Daiki Ikarashi, Tatsuya Kawamura, Keita OGASAWARA, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
Jianli Zhao, Ziyue Zhou, Phei Er Saw, et al.
Journal of the National Cancer Center (2025)
Open Access
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
Huixia Huang, Yuxin Zhou, Chengzhang Shang, et al.
Investigational New Drugs (2025)
Closed Access
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics
Alyssa Bujnak, Samantha Solaru, Krishnansu S. Tewari
Gynecologic Oncology (2025) Vol. 195, pp. 180-191
Open Access
Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates
Qian-Qing Yin, Yanlong Zhang, Xueqing Xie, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study
Fumihiko Urabe, Y Taneda, Naoki Uchida, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 500-500
Open Access | Times Cited: 4
Antibody drug conjugates in the clinic
Edidiong Udofa, Disha Sankholkar, Samir Mitragotri, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 6
Open Access | Times Cited: 4
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Samuele Tardito, Serena Matis, Maria Raffaella Zocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7131-7131
Open Access | Times Cited: 4
Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Linlin Lu, Zihe Niu, Zhujun Chao, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 12
Open Access | Times Cited: 9
The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
Wenge Dong, Wanqi Wang, Chan Cao
ChemMedChem (2024) Vol. 19, Iss. 17
Closed Access | Times Cited: 3
Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer
Chaim Domb, Jorge A. García, Pedro C. Barata, et al.
Therapeutic Advances in Urology (2024) Vol. 16
Open Access | Times Cited: 3
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Hongye Zeng, Wenjing Ning, Xue Liu, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 4, pp. 597-621
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top